Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 3/20 | 0.46 |
| ▸ | CDK2 | P24941 | 3/20 | 0.46 |
| ▸ | CCNA1 | P78396 | 3/20 | 0.46 |
| ▸ | CDK4 | P11802 | 1/20 | 0.46 |
| ▸ | CCND3 | P30281 | 1/20 | 0.46 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.41 |
| ▸ | HPGD | P15428 | 5/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3502504 | 0.97 | CCNA2 (0.46) | CCNA2CDK2CCNA1CDK4CCND3 | |
| SCHEMBL10080623 | 0.84 | CCNA2 (0.44) | CCNA2CDK2CCNA1CDK4CCND3 | |
| SCHEMBL25626841 | 0.83 | BRD4 (0.41) | CCNA2CDK2CCNA1CDK4CCND3 | |
| SCHEMBL3502692 | 0.82 | BRD4 (0.45) | CCNA2CDK2CCNA1BRD4ALDH1A1 | |
| SCHEMBL3503568 | 0.82 | HTT (0.44) | CCNA2CDK2CCNA1CDK4CCND3 | |
| SCHEMBL3797225 | 0.81 | GRM5 (0.47) | CCNA2CDK2CCNA1CDK4CCND3 | |
| SCHEMBL4158743 | 0.81 | BRD4 (0.44) | CCNA2CDK2CCNA1CDK4CCND3 | |
| SCHEMBL3503750 | 0.81 | BRD4 (0.41) | CCNA2CDK2CCNA1CDK4CCND3 | |
| SCHEMBL3504397 | 0.80 | BRD4 (0.43) | CCNA2CDK2CCNA1BRD4ALDH1A1 | |
| SCHEMBL21995756 | 0.80 | BRD4 (0.43) | CCNA2CDK2CCNA1CDK4CCND3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2668188-B1 | TRICYCLIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2016-05-18 | — | — | EP | disclosed |
| EP-2668188-B1 | TRICYCLIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2016-05-18 | — | — | EP | disclosed |
| US-8916577-B2 | Tricyclic derivatives, process for their preparation and their use as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-12-23 | — | — | US | disclosed |
| US-8916577-B2 | Tricyclic derivatives, process for their preparation and their use as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-12-23 | — | — | US | disclosed |
| US-8916577-B2 | Tricyclic derivatives, process for their preparation and their use as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-12-23 | — | — | US | disclosed |
| EP-2668188-A1 | TRICYCLIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2013-12-04 | — | — | EP | disclosed |
| US-20130302416-A1 | TRICYCLIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-11-14 | — | — | US | disclosed |
| US-20130302416-A1 | TRICYCLIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-11-14 | — | — | US | disclosed |
| US-20130302416-A1 | TRICYCLIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-11-14 | — | — | US | disclosed |
| WO-2012101029-A1 | TRICYCLIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-08-02 | — | — | WO | disclosed |
| WO-2012101029-A1 | TRICYCLIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130302416-A1 | TRICYCLIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | CDK1, MAP3K1, MAP3K20 | CCNA2 239/4885CDK2 16/4885CCNA1 244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.